The standard specialty pharmacy workflow for a new script runs roughly like this: script received, patient eligibility checked, prior authorization filed, PA response received, then benefits verification run, then fill decision made. The steps are logical. Each one leads to the next. It feels like a sensible process.
It's also significantly slower than it needs to be — not because any individual step is unnecessarily slow, but because running them sequentially forces each step to wait for the previous one to complete. Prior authorization and benefits verification are treated as dependent steps when, operationally, they are independent. Nothing about running a BV check requires a completed PA first. Nothing about filing a PA requires waiting for BV results. The dependency is assumed, not real.
Understanding the Sequential vs. Parallel Distinction
In a serial (sequential) PA+BV workflow, the timeline looks like this:
- Script received at T+0
- Eligibility check completed at T+15 minutes
- PA submitted at T+60 minutes (after eligibility + staff time for data entry)
- PA response received at T+26 hours (assuming 24-hour commercial payer response)
- BV check run at T+27 hours
- BV response received at T+27.5 hours
- Fill decision made at T+28 hours
In a parallel workflow, the same steps run concurrently from the moment the script arrives:
- Script received at T+0
- Eligibility check, PA submission, and BV check all initiated at T+15 minutes
- BV response received at T+45 minutes
- PA response received at T+24 hours
- Fill decision made at T+24 hours
The difference: 28 hours down to 24 hours — a 4-hour reduction — without any change to payer response time, without any reduction in staff. The only change is running the same steps concurrently instead of sequentially.
Why the Sequential Pattern Persists
The serial PA-then-BV pattern wasn't designed; it emerged from the manual workflow's constraints. When a benefits coordinator had to physically log into separate systems to complete each step, running them sequentially was the only option — one person, one screen, one process at a time.
Most pharmacies carried this pattern forward into their current workflows without explicitly choosing it. When a new PMS was implemented, the workflow was configured to match existing practice. When staff were trained, they learned the sequence that had always been used. No one stopped to ask: in a world where both of these tasks can be automated, why are we treating them as sequential?
There's also a workflow intuition that PA should come first because "you need to know if the drug is covered before you check the patient's benefit details." This logic actually works in reverse. Knowing the patient's copay exposure before the PA is complete is valuable: if the BV reveals the patient faces a $600 out-of-pocket cost regardless of PA approval, that's information the prescriber and patient may want to factor into the treatment decision. The BV result can influence whether you pursue PA aggressively or explore formulary alternatives — and that's a conversation worth having early.
We're not saying the BV result is always a PA-strategy input — in most cases the therapy is already determined and the PA must proceed regardless of cost. We're saying that having BV data in parallel with PA data gives your team more complete information sooner, and the cases where it changes the decision are exactly the ones you don't want to discover late.
The Math on Parallel Processing for High-Volume Pharmacies
The time savings from parallel processing scales with script volume. For a pharmacy processing 50 specialty scripts per week, saving 3–4 hours per script through parallel PA+BV means roughly 150–200 hours of cumulative wait time reduction per week across all scripts in flight. Not staff hours — patient wait time. The number of scripts that clear all required checks and are ready to fill within the same business day goes up substantially.
Consider a growing specialty pharmacy in the mid-Atlantic region processing around 60 specialty scripts weekly, with a payer mix heavily weighted toward commercial plans that respond to PAs within 24–48 hours. Under a serial workflow, most of those scripts aren't fully processed — PA response received plus BV completed — until late on the second or third business day after receipt. Under parallel processing, the same payer response window applies, but the BV work is done by hour one, and the final go/no-go decision is made the moment the PA comes back rather than an hour or two later.
What Parallel Processing Requires from Your Workflow
Running PA and BV in parallel isn't complicated in principle, but it requires a few things to work correctly in practice.
Simultaneous data availability. Both the PA submission and the BV query need the same patient and coverage data from the pharmacy management system. In a manual workflow, this data is entered once for the PA and then re-entered for the BV. In an automated workflow, the data is pulled once from the PMS and routed to both processes simultaneously.
Independent status tracking. PA and BV have separate response timelines and separate action requirements. The tracking system needs to manage both status streams simultaneously and alert staff when either requires attention — an action-required flag on the PA doesn't mean the BV is also blocked, and vice versa.
Decision logic for conflicting results. Occasionally the parallel streams return results that interact: the PA is approved but the BV reveals the approved drug is off-formulary at a high copay tier, triggering a formulary exception question. The workflow needs to surface this intersection clearly rather than burying one result in the other's status stream.
Script triage that captures urgency before either stream starts. For clinically urgent scripts — post-transplant immunosuppressants, oncology agents with tight treatment windows, time-sensitive rare disease therapies — urgency flags should be set at intake, before the PA and BV processes launch, so both streams are prioritized appropriately from the start.
The Fill-Rate Impact
The operational case for parallel processing is clear, but the most important downstream effect is on fill rates and prescription abandonment. Specialty medication abandonment is correlated with wait time. A patient who hears "we're still waiting on insurance" for the third consecutive day is at risk of abandonment — and some of those patients don't call back.
When parallel processing shortens the total time from script receipt to fill-ready decision, more scripts complete within the same business day or the next morning. That shorter cycle reduces the window in which abandonment decisions get made. It doesn't eliminate the cost barriers that drive some abandonment, but it removes the patience-and-uncertainty driver that contributes to others.
The workflow change itself isn't the hard part. The harder part is recognizing that a process inherited from a manual era doesn't have to govern an automated one, and deliberately redesigning it for the environment you're actually operating in.
